Bio

Maren Winnick is a senior managing director and partner at Evercore, where she helps lead the firm’s biotech investment banking business. Ms. Winnick advises her clients on a variety of strategic and financing transactions, including M&A, complex partnering, activism and raid defense. While at Evercore, Ms. Winnick has helped her clients raise more than $20 billion across over 75 IPOs, follow-on offerings, convertibles and private capital raises. Ms. Winnick’s recent M&A transactions include DTx’s $1 billion sale to Novartis, Editas Medicine’s cell therapy sale to Shoreline, Carisma Therapeutic’s sale and reverse merger with Sesen Bio, and Translate Bio’s $3.2 billion sale to Sanofi. Ms. Winnick is co-head of the Evercore Women’s Network and a member of the firm’s Diversity, Equity and Inclusion (DE&I) Leadership Committee. Prior to Evercore, Ms. Winnick was the head of corporate finance at Moderna Therapeutics, helping to lead a $474 million private round financing transaction. She also spent eight years in investment banking at Goldman Sachs in capital markets and M&A, raising over $10 billion across 40-plus transactions while working in the healthcare equity capital markets and advising on a range of healthcare strategic transactions. Earlier in her career, Ms. Winnick was a healthcare consultant at the Monitor Group. She earned a B.A. from Dartmouth College and an MBA from Columbia Business School.